ClinicalTrials.gg

Program

lazertinib

Also written as “Lazertinib”, “Lazertinib 240 mg/160 mg” and “YH25448”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Osteoarthritis, Knee, led by 4 companies.

Furthest: phase 3, since Jul 23, 202018 company-led studies, 6 open or runningNext primary completion: Feb 12, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson125 open or runningphase 3since Jul 23, 2020Aug 21, 2019Feb 12, 2027phase 1 · NCT04077463
Yuhan40 open or runningphase 3since Jan 14, 2020Jan 26, 2017none ahead
Abion11 open or runningphase 2since Sep 4, 2022Sep 4, 2022Feb 2029phase 2 · NCT05541822
BUZZZ Pharmaceuticals10 open or runningphase 2since Jul 22, 2021Jul 22, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Jan 26, 2017.

  1. Aug 30, 2019Phase 1 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04077463 · 701 enrolled · United States, China, France and more
  2. Jan 14, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungYuhan · NCT04248829 · 393 enrolled · Australia, Greece, Hungary and more
  3. May 28, 20202 phase 1 studies in HealthyJohnson & Johnson · NCT04410094, NCT04410081
  4. Jul 23, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04487080 · 1,074 enrolled · United States, Argentina, Australia and more
  5. Jul 22, 2021BUZZZ Pharmaceuticals's first study: phase 2 study in Osteoarthritis, KneeNew to BUZZZ PharmaceuticalsBUZZZ Pharmaceuticals · NCT05007808 · 210 enrolled · Canada
  6. Jul 30, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04988295 · 776 enrolled · United States, Argentina, Belgium and more
  7. Sep 17, 2021Phase 1 study in HealthyJohnson & Johnson · NCT05076877 · 20 enrolled · United States
  8. Nov 2, 2021Phase 1 study in Hepatic ImpairmentJohnson & Johnson · NCT05112952 · 16 enrolled · Germany
  9. Dec 6, 2021Phase 1 study in Carcinoma, Non-Small-Cell LungYuhan · NCT05162274 · 38 enrolled · Korea, Republic of
  10. Sep 4, 2022Abion's first study: phase 2 study in Advanced Solid TumorsNew to AbionAbion · NCT05541822 · 178 planned · United States, Korea, Republic of, Taiwan
  11. Feb 15, 2023Phase 1 study in HealthyJohnson & Johnson · NCT05742594 · 64 enrolled · United States
  12. Jun 1, 2023Phase 1 study in HealthyJohnson & Johnson · NCT05896683 · 72 enrolled · Belgium
  13. Oct 30, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT06667076 · 480 planned · United States, Belgium, Finland and more
  14. May 8, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT07586202 · 68 planned · United States, Canada, China and more

Ahead

  1. Feb 12, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04077463
  2. Mar 2, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT07586202
  3. Feb 2029Primary completion: phase 2 study in Advanced Solid TumorsAbion · NCT05541822
  4. May 23, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT06667076

TargetBeta

EGFR →read by rule
“An orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, including the resistance mutation T790M, exon 19 deletions (Del19), and the L858R mutation, ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07586202Carcinoma, Non-Small-Cell Lung · United States, Canada, China and more2RecruitingJohnson & JohnsonMar 2, 202868
NCT06667076Carcinoma, Non-Small-Cell Lung · United States, Belgium, Finland and more2RecruitingJohnson & JohnsonMay 23, 2029480
NCT05896683Healthy · Belgium1CompletedJohnson & JohnsonSep 1, 202372
NCT05742594Healthy · United States1CompletedJohnson & JohnsonMar 31, 202364
NCT05541822Advanced Solid Tumors · United States, Korea, Republic of, Taiwan2RecruitingAbionFeb 2029178
NCT05162274Carcinoma, Non-Small-Cell Lung · Korea, Republic of1CompletedYuhanJan 14, 202238
NCT05112952Hepatic Impairment · Germany1CompletedJohnson & JohnsonJul 11, 202216
NCT05076877Healthy · United States1CompletedJohnson & JohnsonFeb 10, 202220
NCT04988295Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more3Active, not recruitingJohnson & JohnsonJul 10, 2023776
NCT05007808Osteoarthritis, Knee · Canada2CompletedBUZZZ PharmaceuticalsJan 4, 2023210
NCT04487080Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonAug 11, 20231,074
NCT04410094Healthy · United States1CompletedJohnson & JohnsonDec 30, 202032
NCT04410081Healthy · Netherlands1CompletedJohnson & JohnsonMar 2, 20218
NCT04248829Carcinoma, Non-Small-Cell Lung · Australia, Greece, Hungary and more3CompletedYuhanJul 29, 2022393
NCT04077463Carcinoma, Non-Small-Cell Lung · United States, China, France and more1Active, not recruitingJohnson & JohnsonFeb 12, 2027701
NCT04075396Carcinoma, Non-Small-Cell Lung · United States, Spain, United Kingdom2CompletedJohnson & JohnsonJan 8, 202129
NCT03556436Carcinoma, Non-Small-Cell Lung · Korea, Republic of1CompletedYuhanDec 30, 201824
NCT03046992Carcinoma, Non-Small-Cell Lung · Korea, Republic of2CompletedYuhanJan 8, 2021224

How it is read

Names in the registry

  • “Lazertinib”, 12 entries
  • “Lazertinib 240 mg/160 mg”, 1 entry
  • “YH25448”, 1 entry
  • “Lazertinib(G001)”, 1 entry
  • “Lazertinib(G002)”, 1 entry

Codes read as this program: G001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.